These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 21106656

  • 1. Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD.
    Bernasconi M, Tamm M, Bingisser R, Miedinger D, Leuppi J, Müller B, Christ-Crain M, Stolz D.
    Chest; 2011 Jul; 140(1):91-99. PubMed ID: 21106656
    [Abstract] [Full Text] [Related]

  • 2. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.
    J Am Coll Cardiol; 2007 Nov 13; 50(20):1973-80. PubMed ID: 17996563
    [Abstract] [Full Text] [Related]

  • 3. The prognostic value of midregional proatrial natriuretic peptide in patients with hemorrhagic stroke.
    Fischer M, Katan M, Morgenthaler NG, Seiler M, Müller B, Lackner P, Errath M, Helbok R, Pfausler B, Beer R, Schmutzhard E, Broessner G.
    Cerebrovasc Dis; 2014 Nov 13; 37(2):128-33. PubMed ID: 24481415
    [Abstract] [Full Text] [Related]

  • 4. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD.
    Stolz D, Christ-Crain M, Morgenthaler NG, Miedinger D, Leuppi J, Müller C, Bingisser R, Struck J, Müller B, Tamm M.
    Chest; 2008 Aug 13; 134(2):263-272. PubMed ID: 18490402
    [Abstract] [Full Text] [Related]

  • 5. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, Morgenthaler NG, Bergmann A, Davies JE, Ng LL.
    J Am Coll Cardiol; 2008 May 13; 51(19):1857-64. PubMed ID: 18466800
    [Abstract] [Full Text] [Related]

  • 6. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia.
    Masiá M, Papassotiriou J, Morgenthaler NG, Hernández I, Shum C, Gutiérrez F.
    Clin Chem; 2007 Dec 13; 53(12):2193-201. PubMed ID: 17951293
    [Abstract] [Full Text] [Related]

  • 7. MR-pro-atrial natriuretic peptide (MR-proANP) predicts short- and long-term outcomes in respiratory tract infections: a prospective validation study.
    Vazquez M, Jockers K, Christ-Crain M, Zimmerli W, Müller B, Schuetz P.
    Int J Cardiol; 2012 Apr 05; 156(1):16-23. PubMed ID: 21093937
    [Abstract] [Full Text] [Related]

  • 8. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.
    Müller B, Süess E, Schuetz P, Müller C, Bingisser R, Bergmann A, Stolz D, Tamm M, Morgenthaler NG, Christ-Crain M.
    J Intern Med; 2006 Dec 05; 260(6):568-76. PubMed ID: 17116008
    [Abstract] [Full Text] [Related]

  • 9. Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.
    Theilade S, Hansen TW, Goetze JP, Rossing P.
    Am J Hypertens; 2015 Jun 05; 28(6):772-9. PubMed ID: 25468806
    [Abstract] [Full Text] [Related]

  • 10. MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI.
    Lindberg S, Jensen JS, Pedersen SH, Galatius S, Goetze JP, Mogelvang R.
    Eur J Prev Cardiol; 2015 Jun 05; 22(6):693-700. PubMed ID: 24906365
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia.
    Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ.
    Intensive Care Med; 2008 Nov 05; 34(11):2084-91. PubMed ID: 18523752
    [Abstract] [Full Text] [Related]

  • 12. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ.
    Krüger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T, CAPNETZ Study Group.
    Thorax; 2010 Mar 05; 65(3):208-14. PubMed ID: 20335288
    [Abstract] [Full Text] [Related]

  • 13. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG, Bergmann A, Huelsmann M, Pacher R.
    J Am Coll Cardiol; 2009 May 12; 53(19):1783-90. PubMed ID: 19422985
    [Abstract] [Full Text] [Related]

  • 14. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S, Hage C, Linde C, Daubert JC, Donal E, Gabrielsen A, Mellbin L, Lund LH.
    Int J Cardiol; 2015 May 12; 189():6-11. PubMed ID: 25885866
    [Abstract] [Full Text] [Related]

  • 15. Midregional pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction.
    Meune C, Twerenbold R, Drexler B, Balmelli C, Wolf C, Haaf P, Reichlin T, Irfan A, Reiter M, Zellweger C, Meissner J, Stelzig C, Freese M, Capodarve I, Mueller C.
    Am J Cardiol; 2012 Apr 15; 109(8):1117-23. PubMed ID: 22257708
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
    Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T, German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group.
    Am J Respir Crit Care Med; 2010 Dec 01; 182(11):1426-34. PubMed ID: 20639437
    [Abstract] [Full Text] [Related]

  • 17. The natriuretic peptide MR-proANP predicts all-cause mortality and adverse outcome in community patients: a 10-year follow-up study.
    Odermatt J, Hersberger L, Bolliger R, Graedel L, Christ-Crain M, Briel M, Bucher HC, Mueller B, Schuetz P.
    Clin Chem Lab Med; 2017 Aug 28; 55(9):1407-1416. PubMed ID: 28107168
    [Abstract] [Full Text] [Related]

  • 18. Midregional-proAtrial Natriuretic Peptide and High Sensitive Troponin T Strongly Predict Adverse Outcome in Patients Undergoing Percutaneous Repair of Mitral Valve Regurgitation.
    Wöhrle J, Karakas M, Trepte U, Seeger J, Gonska B, Koenig W, Rottbauer W.
    PLoS One; 2015 Aug 28; 10(9):e0137464. PubMed ID: 26368980
    [Abstract] [Full Text] [Related]

  • 19. Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP.
    Boeck L, Eggimann P, Smyrnios N, Pargger H, Thakkar N, Siegemund M, Marsch S, Rakic J, Tamm M, Stolz D.
    Eur Respir J; 2011 Mar 28; 37(3):595-603. PubMed ID: 20530040
    [Abstract] [Full Text] [Related]

  • 20. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
    Elmas E, Brueckmann M, Lang S, Kälsch T, Haghi D, Sueselbeck T, Dempfle CE, Borggrefe M.
    Int J Cardiol; 2008 Aug 18; 128(2):244-9. PubMed ID: 17673312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.